Patents
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
04/2011
04/27/2011CN102036665A Novel uses of sodium 4-phenylbutyrate (4 PBA) and the pharmaceutically acceptable salts thereof
04/27/2011CN102036663A Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
04/27/2011CN102036660A Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
04/27/2011CN102030824A Monoclonal antibody of hepatitis B virus X protein and use thereof
04/27/2011CN102028949A Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
04/27/2011CN102028948A Manganoporphyrin-alkylating agent combined medicine for treating tumors
04/27/2011CN102028947A Inhibitor, inhibitor composition and inhibiting method of FAM3B gene, fatty liver treatment method and pharmaceutical application of inhibitor
04/27/2011CN102028935A Method for forecasting, preventing and treating septicemia and septic shock and kit
04/27/2011CN102028670A Composite capsule containing telmisartan and calcium ion channel antagonist
04/27/2011CN102028645A Compositions comprising an nfkb-inhibitor and a non-retinoid collagen promoter
04/27/2011CN101327190B Anti-tumor long-circulating target liposomes for injections
04/26/2011US7932371 Tick octopamine receptor nucleic acid molecules
04/26/2011US7932367 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
04/26/2011US7932363 Antibody that binds human eosinophil-derived basic protein
04/26/2011US7932076 Compositions for culturing spirochetes
04/26/2011US7931917 Phospholipid-free, having a D50 particle size of less than 500 nm, and having a surface stabilizer; improved pharmacokinetic profiles and reduced fed/fasted variability
04/26/2011CA2529538C Pyridoxamine for the treatment of diabetic kidney disease
04/26/2011CA2479133C 2-4-diaminopyrimidine derivatives
04/26/2011CA2477657C Cathepsin cysteine protease inhibitors
04/26/2011CA2450728C Composition for the treatment of diseases which affect animals' hooves
04/26/2011CA2446619C Permeation enhancers
04/26/2011CA2446112C A method for regulating immune function in primates using the foxp3 protein
04/26/2011CA2416572C Bispecific antibody for target cell-specific stimulation of the apo-1 cell surface receptor
04/26/2011CA2408838C Drug/drug delivery systems for the prevention and treatment of vascular disease
04/26/2011CA2402099C Methods for the treatment of primary headache disorders using prostanoid ep4 receptor antagonists, and assays for agents for such treatment
04/26/2011CA2388656C Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma
04/26/2011CA2371109C Improved pharmaceutical formulations
04/26/2011CA2359945C Inhibitors of crystallization in a solid dispersion
04/26/2011CA2337988C Inhibitors of proteasomal activity for stimulating bone and hair growth
04/26/2011CA2326141C Use of receptor of a ror family for screening substances useful for the treatment of atherosclerosis
04/26/2011CA2306024C Buccal, polar and non-polar spray or capsule
04/26/2011CA2298934C Vectors derived from antibodies for transferring substances into cells
04/21/2011WO2011047065A1 Recombinant human cc10 protein for treatment of influenza
04/21/2011WO2011046811A1 Combinations of a specific hcv ns5a inhibitor and an hcv ns3 protease inhibitor
04/21/2011WO2011046160A1 Method for screening of substance capable of preventing virus infection, and agent for preventing virus infection
04/21/2011WO2011045075A1 Compositions comprising tramadol and celecoxib in the treatment of pain
04/21/2011WO2011045068A2 Pharmaceutical composition containing cannabinoid-receptor antagonists
04/21/2011US20110092674 Non-Functional P2X7 Receptor
04/21/2011US20110092528 Piperidinyl compounds that selectively bind integrins
04/21/2011US20110092523 Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
04/21/2011US20110092482 Methods and compositions
04/21/2011US20110092471 Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
04/21/2011US20110092442 Anticancer agent containing bl-angiostatin
04/21/2011US20110091920 METHOD OF DIAGNOSING A CLINICAL CONDITION BY DETECTION OF A PAPP-A/proMBP COMPLEX
04/21/2011US20110091892 Methods for the Diagnosis and Treatment of Lung Cancer
04/21/2011US20110091876 Zcytor19 polynucleotides, polypeptides, antibodies and methods of use
04/21/2011US20110091578 Method of stimulating tissue healing
04/21/2011US20110091556 Antimicrobial compositions and methods of use
04/21/2011US20110091541 Preparation of formulations of angiotensin II at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications
04/21/2011US20110091516 Muscle-based grafts/implants
04/21/2011US20110091472 Compositions for treating psoriasis
04/21/2011US20110091413 Therapeutic use of interleukin-2 mutants
04/21/2011US20110091406 Composition and method for protecting labile active components during high temperature drying
04/21/2011US20110091379 Method for treating tumors and their metastases
04/21/2011DE202009017772U1 Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid Combination products with cytokine antagonist and corticosteroid
04/21/2011CA2777560A1 Combinations of a specific hcv ns5a inhibitor and an hcv ns3 protease inhibitor
04/20/2011EP2312482A1 Systems and methods for providing a stem cell bank
04/20/2011EP2311980A1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
04/20/2011EP2311979A1 Compositions, kits and methods for identification, assessment, prevention and therapy of cervical cancer
04/20/2011EP2311978A1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
04/20/2011EP2311960A2 Bv8 nucleic acids and polypeptides with mitogenic activity
04/20/2011EP2311953A1 Bone/joint disease susceptibility gene and use thereof
04/20/2011EP2311951A1 Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
04/20/2011EP2311950A1 Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
04/20/2011EP2311882A1 Reducing the immunogenicity of fusion proteins
04/20/2011EP2311875A1 Treatment with anti-VEGF antibodies
04/20/2011EP2311869A1 Use of mammalian cytokine; related reagents
04/20/2011EP2311862A2 Differential in tumour gene products and use of same
04/20/2011EP2311861A2 Differential in tumour gene products and use of same
04/20/2011EP2311860A2 Differential in tumour gene products and use of same
04/20/2011EP2311852A1 Anti-infarction molecules
04/20/2011EP2311849A1 Specific binding agents of human angiopoietin-2
04/20/2011EP2311497A1 Use of oligouronates
04/20/2011EP2311496A1 A combination of morphine and oxycodone for use in the alleviation or prevention of pain
04/20/2011EP2311495A1 Vascularization inhibitors
04/20/2011EP2311494A1 Histone modification inhibitor specific to target gene
04/20/2011EP2311490A2 Uses of antibodies to aminophospholipids for cancer treatment
04/20/2011EP2311465A1 Remedies for diseases to be applied to eye
04/20/2011EP2311461A1 Methods for treating cancer by inhibiting mitosis using pyrrolo[2,3-d]pyrimidines
04/20/2011EP2311453A1 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
04/20/2011EP2311452A1 Topical composition comprising n-acetyl glucosamine
04/20/2011EP2311449A1 Orally administrated food supplement comprising carnitine
04/20/2011EP2311446A1 Compositions comprising Tramadol and Celecoxib in the treatment of pain
04/20/2011EP2311443A1 Pharmaceutical composition containing cannabinoid-receptor 2 antagonists
04/20/2011EP2311441A1 Dosage formulations for acetylcholinesterase inhibitors
04/20/2011EP2310052A2 Acne treatment compositions comprising nanosilver and uses
04/20/2011EP2310051A1 Combination of a parp inhibitor and an akt kinase activating compound
04/20/2011EP2310050A1 Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
04/20/2011EP2310039A1 Fgf-9 and its use relating to blood vessels
04/20/2011EP2310007A2 Improving renal function with quercetin-containing compositions
04/20/2011EP2310006A2 Treating cancer
04/20/2011EP2310005A2 Treatment of inflammatory conditions with isothiocyanates
04/20/2011EP2061444B1 Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy
04/20/2011EP1859793B1 Novel combinational use of a sulfonamide compound in the treatment of cancer
04/20/2011EP1569657B1 Use of amphiphilic lipids for the preparation of a pharmaceutical composition for reducing tumor metastasis
04/20/2011EP1505963B1 Hepatitis c virus inhibitors
04/20/2011EP1392319B1 Hypotensive lipid (prostaglandin) and timolol compositions and methods of using same
04/20/2011EP1385993B1 Method of detecting and treating tuberous sclerosis complex associated disorders
04/20/2011EP1224461B1 Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
04/20/2011EP1082415B1 Methods useful for modulation of angiogenesis using tyrosine kinase src